Biomarkers · Coagulation
Angiopoietin-2
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.29×per 1 SD increment in serum Ang-2 (95% CI 1.19–1.39) · Study of Health in Pomerania (SHIP), population-based sample, mean age 54.4 years, Germany
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in Angiopoietin-2, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Oral sildenafil every 8 hours for 15 days vs placebo in stable patients on durable left ventricular assist device support | Angiopoietin-2 changed by -5% (-11 to -4) on sildenafil vs +3% (-5 to 15) on placebo at day 15 (P = .039); twenty participants | RCT | Saeed O, Patel SR, Farooq M, et al. ESC Heart Fail. 2026;13(3):xvag099. |
| supplement | Two oral doses of cholecalciferol 300,000 IU (baseline and week 8) vs placebo in vitamin D-deficient adults with non-diabetic CKD stage 3-4 | Serum angiopoietin-2 changed -0.27 ng/mL (95% CI -1.09 to 0.55) vs placebo at 16 weeks; not significant; n=120 randomised | RCT | Kaur J, Kamboj K, Yadav AK, et al. PLoS One. 2022;17(6):e0268946. |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ COVID-19, critical illness · critically ill vs non-critically ill COVID-19 patients | +2.388 ng/mL (95% CI 1.121 to 3.655) | critically ill vs non-critically ill COVID-19 patients · Hospitalised COVID-19 patients, 27 studies | meta analysis · PMID 34702152 |
| ↑ COVID-19, poor outcome · patients with poor outcome vs good outcome | SMD +1.06 (95% CI 0.6 to 1.51) | poor vs good outcome, COVID-19 patients · COVID-19 patients, 74 studies | meta analysis · PMID 36943015 |
| ↑ Lung cancer with lymph node metastasis · serum Ang-2 in lung cancer patients with vs without lymph node metastasis | SMD +1.06 (95% CI 0.57 to 1.56) | lymph node metastasis vs no metastasis, lung cancer patients · Lung cancer patients, 20 studies | meta analysis · PMID 28906403 |
Genetic predisposition
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↕ MCPH1 rs2442517 and ABO rs8176746 (top GWAS loci) · proportion of inter-individual variation in circulating Ang-2 explained by top genetic loci | +1.7% | variance explained by top loci · Framingham Heart Study participants (replication in SHIP, n=3184) | gwas · PMID 25552591 |